Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.

Carta Acesso aberto Revisado por pares

Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.

2005; Elsevier BV; Volume: 45; Issue: 3 Linguagem: Inglês

10.1016/j.jacc.2004.11.009

ISSN

1558-3597

Autores

Thomas Wichter, Günter Breithardt,

Tópico(s)

Cardiac pacing and defibrillation studies

Resumo

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a frequent cause of ventricular tachycardia (VT) and sudden death in apparently healthy adolescents and young adults. In this issue of the Journal , Hodgkinson et al. ([1][1]) report on the role of implantable cardioverter-defibrillators (

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.